NeueHealth Beheer

Beheer criteriumcontroles 3/4

De CEO NeueHealth is Mike Mikan, benoemd in Jan2019, heeft een ambtstermijn van 5.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.90M, bestaande uit 13.1% salaris en 86.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.79% van de aandelen van het bedrijf, ter waarde $ 320.92K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 5.3 jaar.

Belangrijke informatie

Mike Mikan

Algemeen directeur

US$9.9m

Totale compensatie

Percentage CEO-salaris	13.1%
Dienstverband CEO	5.8yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Oct 11

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Aug 13

Bright Health Group Takes Cost Actions To Effect Turnaround

Jul 21

Bright Health Group: Examining A Dumpster Fire

Jan 04

Analyse CEO-vergoeding

Hoe is Mike Mikan's beloning veranderd ten opzichte van NeueHealth's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$28m
Jun 30 2024	n/a	n/a	-US$495m
Mar 31 2024	n/a	n/a	-US$510m
Dec 31 2023	US$10m	US$1m	-US$563m
Sep 30 2023	n/a	n/a	-US$825m
Jun 30 2023	n/a	n/a	-US$407m
Mar 31 2023	n/a	n/a	-US$447m
Dec 31 2022	US$10m	US$1m	-US$521m
Sep 30 2022	n/a	n/a	-US$373m
Jun 30 2022	n/a	n/a	-US$513m
Mar 31 2022	n/a	n/a	-US$450m
Dec 31 2021	US$181m	US$1m	-US$330m
Sep 30 2021	n/a	n/a	-US$534m
Jun 30 2021	n/a	n/a	-US$293m
Mar 31 2021	n/a	n/a	-US$266m
Dec 31 2020	US$5m	US$600k	-US$161m

Compensatie versus markt: De totale vergoeding ($USD 9.90M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 652.28K ).

Compensatie versus inkomsten: De vergoeding van Mike is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mike Mikan (52 yo)

5.8yrs

Tenure

US$9,898,059

Compensatie

Mr. George Lawrence Mikan, III, also known as Mike, is Chief Executive Officer at NeueHealth, Inc. (formerly known as Bright Health Group, Inc.) (formerly Bright Health, Inc) since April 2020 and its Presi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Sheehy	Co-Founder & Chairman	9.8yrs	geen gegevens	3.1% $ 1.3m
George Mikan	Vice Chairman	5.8yrs	US$9.90m	0.79% $ 320.9k
Jay Matushak	Chief Financial Officer	1.5yrs	US$1.77m	0.11% $ 46.9k
Tomas Orozco	Executive Vice President of Consumer Care	less than a year	US$1.59m	0.062% $ 25.2k
Jeffrey Scherman	Chief Accounting Officer	no data	geen gegevens	0.044% $ 18.2k
Jeff Craig	General Counsel & Corporate Secretary	2.7yrs	US$832.55k	0.042% $ 17.0k
Stacy Conti	Chief People Officer	no data	geen gegevens	geen gegevens
Joaquin Baralt	President of Value-Based Care	no data	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NEUE wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Sheehy	Co-Founder & Chairman	9.8yrs	geen gegevens	3.1% $ 1.3m
George Mikan	Vice Chairman	5.8yrs	US$9.90m	0.79% $ 320.9k
Andrew Slavitt	Independent Director	3.3yrs	US$153.68k	0.17% $ 67.6k
Jeffrey Immelt	Independent Director	4.6yrs	US$173.68k	0.16% $ 66.4k
Mohamad Makhzoumi	Independent Director	8.7yrs	US$163.68k	0.072% $ 29.4k
Linda Gooden	Independent Director	5.8yrs	US$163.68k	1.21% $ 494.3k
Manuel Kadre	Independent Lead Director	4yrs	US$188.68k	0.28% $ 113.9k
Stephen H. Kraus	Independent Director	8.7yrs	US$163.68k	0.072% $ 29.4k
Matthew Manders	Independent Director	2.7yrs	US$153.68k	0.076% $ 30.9k
Kedrick Adkins	Independent Director	4.8yrs	US$178.68k	1.21% $ 494.3k

5.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NEUE wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

NeueHealth Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Recent updates

Third quarter 2024 earnings released: US$6.78 loss per share (vs US$72.52 loss in 3Q 2023)

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Insufficient new directors

Second quarter 2024 earnings released: US$6.42 loss per share (vs US$8.55 loss in 2Q 2023)

NeueHealth, Inc. Updates Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q2, 2024 Results on Aug 07, 2024

New major risk - Financial position

NeueHealth, Inc. announced that it has received $150 million in funding

New minor risk - Shareholder dilution

NeueHealth, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$2.31 loss per share (vs US$9.04 loss in 1Q 2023)

NeueHealth, Inc. to Report Q1, 2024 Results on May 08, 2024

NeueHealth, Inc., Annual General Meeting, May 02, 2024

Vice Chairman recently sold US$59k worth of stock

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$70.72 loss per share (vs US$98.28 loss in FY 2022)

NeueHealth, Inc. Provides Earnings Guidance for the Year 2024

NeueHealth, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Third quarter 2023 earnings released: US$72.52 loss per share (vs US$40.11 loss in 3Q 2022)

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Revenue and earnings growth

Bright Health Group, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Bright Health Group, Inc. Announces Leaving of Jeff Cook as Chief Operating Officer, Effective October 13, 2023

Consensus EPS estimates upgraded to US$51.32 loss

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Revises Its Financial Outlook for 2023

Bright Health Group, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 47% to US$200

Florence Labs, Inc. acquired Zipnosis, Inc. from Bright Health Group, Inc. (NYSE:BHG).

Price target decreased by 14% to US$1.70

Bright Health Group, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Bright Health Group Announces Chief Financial Officer Changes

Vice Chairman recently sold US$158k worth of stock

Price target decreased by 24% to US$1.50

Consensus EPS estimates fall by 14%

Full year 2022 earnings released: US$1.23 loss per share (vs US$3.02 loss in FY 2021)

Bright Health Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Bright Health Group: Stock Price Has Been Too Heavily Beaten Down

Bright Health Group expects FY23 revenue to be below consensus

Independent Director recently bought US$248k worth of stock

Bright Health Group Receives Continued Listing Standard Notice from NYSE

Bright Health receives non-compliance notice from NYSE

Independent Lead Director recently bought US$294k worth of stock

Price target decreased to US$2.07

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2022

Bright Health Group reports Q3 mixed earnings; revises Fy22 guidance

Bright Health Group, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Bright Health Group, Inc. announced that it has received $175 million in funding from a group of investors

Bright Health Group, Inc. Provides Revenue Guidance for the Year 2023

Bright Health narrows footprint to only offer Medicare Advantage in California, Florida

Analysts Have Been Trimming Their Bright Health Group, Inc. (NYSE:BHG) Price Target After Its Latest Report

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Bright Health Group, Inc. Provides Revenue Guidance for the Full Year 2022

Bright Health Group, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Bright Health Group Takes Cost Actions To Effect Turnaround

Price target decreased to US$2.76

Bright Health Group, Inc.(NYSE:BHG) dropped from Russell 2000 Growth Index

Bright Health Group Expands Executive Team as It Drives Performance in Scaled Businesses

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Bright Health Group, Inc. to Report Q1, 2022 Results on May 04, 2022

Bright Health Group, Inc., Annual General Meeting, May 13, 2022

Consensus forecasts updated